Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protea, MSK, Dana-Farber Enter Collaborative Research Agreement

Published: Wednesday, April 30, 2014
Last Updated: Wednesday, April 30, 2014
Bookmark and Share
Protea's LAESI technology to be used to profile cancer cells to improve diagnosis and treatment selection

Protea Biosciences Group, Inc. announced it has begun a collaborative research initiative with the Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer Institute (Dana-Farber) that uses Protea’s next generation LAESI direct molecular imaging technology to analyze cancer cells. The initial focus is early stage lung adenocarcinoma. 

The studies will utilize LAESI technology to generate molecular data profiles of cancer cells in tissue and biofluids to improve the understanding of a cancer’s origin. Protea’s proprietary LAESI technology generates very large molecular data profiles of cancer cells in their native state, without the need for time-consuming sample preparation. 

The principal investigators are Robert J. Downey, M.D. and Andre Moreira, M.D. at MSK and Franziska Michor, Ph.D. at Dana-Farber. 

“We are pleased to have this opportunity to apply our LAESI technology to provide improved molecular profiling of cancer cells and tissue samples,” commented Steve Turner, Protea’s CEO. He added, “In the future we anticipate applying our direct molecular profiling technology to other tissue sample types, including 3 dimensional cell cultures and synthetic biology tissues, to provide comprehensive molecular profiling of tumors rapidly and directly. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protea Announces License Agreement with Yale
Company has announced an exclusive license agreement with Yale for new technology for detecting malignant melanoma skin cancer.
Tuesday, April 26, 2016
Scientific News
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Biomarkers That Could Help Give Cancer Patients Better Survival Estimates Discovered
UCLA research may also help scientists suppress dangerous genetic sequences.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!